Paul DePietro

759 total citations · 1 hit paper
41 papers, 451 citations indexed

About

Paul DePietro is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul DePietro has authored 41 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 16 papers in Immunology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul DePietro's work include Cancer Immunotherapy and Biomarkers (26 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Genomics and Diagnostics (7 papers). Paul DePietro is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Genomics and Diagnostics (7 papers). Paul DePietro collaborates with scholars based in United States, Netherlands and United Kingdom. Paul DePietro's co-authors include Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Razelle Kurzrock, Shumei Kato, Yu Fujiwara, Hirotaka Miyashita, Daisuke Nishizaki, Suzanna Lee and Sean T. Glenn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Paul DePietro

35 papers receiving 442 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy

2022 195 citations Yu Fujiwara, Shumei Kato et al. profile →

Peers

Countries citing papers authored by Paul DePietro

Since Specialization

Citations

This map shows the geographic impact of Paul DePietro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul DePietro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul DePietro more than expected).

Fields of papers citing papers by Paul DePietro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul DePietro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul DePietro. The network helps show where Paul DePietro may publish in the future.

Co-authorship network of co-authors of Paul DePietro

This figure shows the co-authorship network connecting the top 25 collaborators of Paul DePietro. A scholar is included among the top collaborators of Paul DePietro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul DePietro. Paul DePietro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations	JCO Precision Oncology	Daisuke Nishizaki, Sharon H. Choi et al.	1
2	B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades	ImmunoTargets and Therapy	Daisuke Nishizaki, Hirotaka Miyashita et al.	0
3	PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome	npj Genomic Medicine	Hui‐Zi Chen, Na Hyun Kim et al.	4
4	Viewing the immune checkpoint VISTA: landscape and outcomes across cancers	ESMO Open	Daisuke Nishizaki, Razelle Kurzrock et al.	18
5	The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer	Oncology and Therapy	Mary Nesline, Vivek Subbiah et al.	3
6	OX40/OX40 ligand and its role in precision immune oncology	Cancer and Metastasis Reviews	Shumei Kato, Daisuke Nishizaki et al.	28
7	High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy	iScience	Yu Fujiwara, Shumei Kato et al.	6
8	Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer	Journal of Translational Medicine	R. J. Seager, Shuang Gao et al.	3
9	Abstract 6393: The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors	Cancer Research	Shumei Kato, Daisuke Nishizaki et al.	1
10	PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes	Cancers	Mary Nesline, Rebecca A. Previs et al.	4
11	Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity	Cancer Medicine	Razelle Kurzrock, Daisuke Nishizaki et al.	9
12	LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics	Cancer Medicine	Jacob J. Adashek, Shumei Kato et al.	24
13	T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy	npj Genomic Medicine	Hirotaka Miyashita, Razelle Kurzrock et al.	15
14	BTLA transcriptomic expression correlates with high levels of PD-1, PD-L2, and CTLA-4 checkpoints and with its ligand, HVEM, across diverse solid cancers.	Journal of Clinical Oncology	Sharon Choi, Razelle Kurzrock et al.	0
15	The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.	Journal of Clinical Oncology	Mary Nesline, Paul DePietro et al.	1
16	A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors	PLoS ONE	Jeffrey M. Conroy, Sarabjot Pabla et al.	24
17	Immune profiling and immunotherapeutic targets in pancreatic cancer	Annals of Translational Medicine	Felicia L. Lenzo, Shumei Kato et al.	16
18	Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response	Biomarker Research	Sarabjot Pabla, R. J. Seager et al.	18
19	Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC	Journal of Thoracic Oncology	Sai Yendamuri, Joseph Barbi et al.	24
20	Quantification of the impact of PSI:Biology according to the annotations of the determined structures	BMC Structural Biology	Paul DePietro, William A. McLaughlin et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact